Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

IF 3 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-07-29 DOI:10.1080/14796694.2024.2355079

Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes

{"title":"Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.","authors":"Alessandra Tedeschi, Constantine S Tam, Roger G Owen, Christian Buske, Véronique Leblond, Meletios Dimopoulos, Ramón Garcia-Sanz, Jorge J Castillo, Judith Trotman, Steven P Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Y Chan, Aileen Cohen, Shengnan Chen, Gisoo Barnes","doi":"10.1080/14796694.2024.2355079","DOIUrl":null,"url":null,"abstract":"Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations.Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2355079","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods: Patient-reported outcomes were exploratory end points assessed using the EORTC QLQ-C30 and EQ-5D-5L VAS scores. Results: Overall, 201 patients (102 zanubrutinib; 99 ibrutinib) were enrolled. Clinically meaningful differences were observed in diarrhea and nausea/vomiting in both the intent-to-treat population and in patients attaining very good partial response (VGPR) in earlier cycles of treatment, as well as in long-term physical functioning and fatigue in patients achieving VGPR. Conclusion: Treatment with zanubrutinib was associated with greater improvements in health-related quality of life compared with ibrutinib in patients with WM and MYD88 mutations.Clinical Trial Registration: NCT03053440 (ClinicalTrials.gov).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

瓦尔登斯特伦巨球蛋白血症患者的健康相关生活质量：ASPEN 试验结果。

ASPEN 是一项随机、开放标签的 III 期研究，比较了赞鲁替尼和伊布替尼对瓦尔登斯特伦巨球蛋白血症（WM）患者的治疗效果。材料与方法：患者报告结果为探索性终点，使用 EORTC QLQ-C30 和 EQ-5D-5L VAS 评分进行评估。结果共有 201 名患者（102 名扎鲁替尼患者；99 名伊布替尼患者）入组。在意向治疗人群和早期治疗周期中获得很好部分应答（VGPR）的患者中，观察到腹泻和恶心/呕吐方面存在有临床意义的差异；在获得 VGPR 的患者中，观察到长期身体功能和疲劳方面存在有临床意义的差异。结论在WM和MYD88突变的患者中，与伊布替尼相比，扎努鲁替尼治疗与健康相关的生活质量改善更大：NCT03053440（ClinicalTrials.gov）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.